NCT06309277

A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD

A Two-Part Controlled Clinical Study to Evaluate Safety, Tolerability, Response, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of GM-1020 in Patients With Major Depressive Disorder

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 46 (actual)
• Sponsor: Gilgamesh Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The aim of this Phase 2a study in patients with MDD is to assess safety and tolerability and preliminary antidepressant efficacy.

Conditions

• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	GM-1020	N-methyl-D-aspartate (NMDA) receptor antagonist

Timeline

• Start date: 2024-02-01
• Primary completion: 2025-03-04
• Completion: 2025-03-27
• First posted: 2024-03-13
• Last updated: 2025-12-16

Locations

1 site across 1 country: United Kingdom